Welcome to our dedicated page for Tevogen Bio SEC filings (Ticker: TVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tevogen Bio Holdings Inc. (TVGN) SEC filings page on Stock Titan aggregates the company’s official disclosures from the U.S. Securities and Exchange Commission, offering a structured view into this clinical-stage biotechnology issuer’s regulatory record. As a Nasdaq-listed company, Tevogen files periodic reports and current reports that detail its financial performance, operating strategy, and material events.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include audited or reviewed financial statements, management’s discussion and analysis, and commentary on Tevogen’s capital-efficient, cost-disciplined business model. For a company focused on precision T cell therapies and AI-enabled drug discovery, these filings provide context on research and development spending, general and administrative expenses, and non-GAAP measures such as adjusted loss from operations that Tevogen uses to describe operational performance.
Current reports on Form 8-K capture significant events, including listing and compliance matters. For example, Tevogen disclosed via Form 8-K that it received a Nasdaq notice regarding non-compliance with the $1.00 per share minimum bid price requirement, outlining the applicable compliance period and potential paths to regain compliance. Such filings help investors understand listing status and associated timelines.
The filings page also offers access to information related to equity structure, warrants, and other securities, as well as any proxy materials and, where applicable, insider transaction reports on Form 4. Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify items such as changes in operating loss, capital structure, or risk disclosures. Real-time updates from EDGAR ensure that new TVGN filings, from 10-Qs to 8-Ks, appear promptly with accessible explanations for investors analyzing Tevogen’s financial and regulatory trajectory.
Tevogen Bio Holdings Inc. updated its prospectus supplement to report stockholder approvals from a February 19, 2026 special meeting. Shareholders approved an amendment adding 100,000,000 shares to the 2024 Omnibus Incentive Plan and approved a reverse stock split between 1:25 and 1:85, with the exact ratio and timing to be determined by the Board in its sole discretion.
The filing states there were 201,522,282 shares of Common Stock issued and outstanding as of January 21, 2026. Vote tallies show strong support for both proposals; the Plan Amendment received 147,777,455 votes for and the Reverse Stock Split Proposal received 176,344,447 votes for.
Tevogen Bio Holdings Inc. reported that stockholders approved two key proposals at a special meeting. First, they approved an amendment to the 2024 Omnibus Incentive Plan, adding 100,000,000 shares of common stock available for equity awards, which can be adjusted if a future reverse stock split occurs.
Stockholders also approved an amendment to the Certificate of Incorporation authorizing a reverse stock split of issued and outstanding common shares at a ratio between 1:25 and 1:85, with the exact ratio and timing left to the Board’s discretion, if implemented. At the record date, 201,522,282 shares were outstanding, and 182,412,517 shares were represented at the meeting. Both proposals received strong support based on the reported vote tallies.
Tevogen Bio Holdings Inc. insider plans to sell common stock under Rule 144. A holder has filed to sell 330,000 shares of Tevogen Bio common stock through Fidelity Brokerage Services LLC on or around 02/06/2026 on the NASDAQ, with an aggregate market value of $103,224.00.
The shares come from gifts received on 12/12/2025 (230,000 shares from Ryan Saad) and 12/16/2025 (100,000 shares from Kirt Desai). The filing also notes a prior sale of 15,500 Tevogen Bio shares for $5,116.55 on 12/31/2025 by Shrimad Rachandra Love & Care.
Tevogen Bio Holdings Inc. reported that its Board of Directors has expressed an intention to evaluate the potential declaration of a one-time special cash dividend for shareholders. Any dividend would follow the satisfaction of financial milestones that will be determined at a future date.
The update was shared through a press release issued on January 30, 2026 and furnished under a Regulation FD disclosure, signaling an early-stage, exploratory step rather than a finalized dividend decision.
Tevogen Bio Holdings Inc. has called a special virtual stockholder meeting for February 19, 2026 to vote on two major proposals.
Proposal 1 would amend the 2024 Omnibus Incentive Plan to increase the shares of common stock reserved for equity awards by 100 million, from 58,951,432 to 158,951,432. As of the record date, only 9,469,839 shares remained available for new grants, and directors and executive officers collectively held 70.51% of the voting power. The plan also includes an annual “evergreen” increase of up to 5.0% of shares outstanding each year through 2034.
Proposal 2 would amend the certificate of incorporation to authorize a reverse stock split of outstanding common shares at a ratio between 1‑for‑25 and 1‑for‑85, without reducing the current authorization of 800,000,000 shares. The board cites a Nasdaq notice received after the stock traded below $1.00 for 30 days; on January 23, 2026, the shares closed at $0.3499. The split is intended to help regain Nasdaq minimum bid compliance, while fractional shares would be settled in cash.
Tevogen Bio Holdings Inc. is asking stockholders at a February 19, 2026 virtual special meeting to approve two major proposals affecting its capital structure and compensation plans. Proposal 1 would amend the 2024 Omnibus Incentive Plan to raise the share reserve for equity awards by 100 million shares of common stock, from 58,951,432 to 158,951,432, with 9,469,839 shares still available as of the record date. The plan also includes an “evergreen” feature that can add up to 5% of outstanding shares each year through 2034.
Proposal 2 would amend the certificate of incorporation to authorize a reverse stock split of the currently issued and outstanding common stock at a ratio between 1-for-25 and 1-for-85, at the Board’s discretion, without reducing the 800,000,000 authorized share count. The Board cites a Nasdaq deficiency notice received after the stock traded below $1.00, and notes the January 15, 2026 closing price of $0.3264 per share. Directors and executive officers collectively hold 70.51% of voting power, and the CEO has received large long-term restricted stock awards, including a 19,348,954-share grant tied to the 2024 business combination.
Tevogen Bio Holdings Inc.'s Chief Financial Officer reported gifting 300,000 shares of common stock in a recent insider transaction.
The filing states that 100,000 shares were donated to Shrimad Rajchandra Love and Care USA, Inc. and 200,000 shares to Shrimad Rajchandra Mission Dharampur (USA), Inc., both described as charitable entities. Following these gifts, the reporting person beneficially owns 10,149,186 shares of Tevogen Bio common stock directly.
Tevogen Bio Holdings Inc. reported that a company insider who is a director, chief executive officer and 10% owner gifted 460,000 shares of common stock on December 11, 2025. The transaction was coded as a gift at a reported price of $0 per share.
The gift consisted of 230,000 shares to Shrimad Rajchandra Love and Care USA, Inc. and 230,000 shares to Warren Township Honorary P.B.A., Inc., both described as charitable entities. After this transaction, the reporting person beneficially owned 124,334,453.322 shares directly and 193,924 shares indirectly through a spouse.
Tevogen Bio Holdings Inc. filed a Rule 424(b)(3) prospectus supplement to update its S‑1 with the attached Quarterly Report for the period ended September 30, 2025. The company remains a clinical‑stage developer of off‑the‑shelf precision T cell therapies and reports no product revenue.
For Q3 2025, Tevogen reported a net loss of
Common shares outstanding were 197,391,411 as of September 30, 2025, and 198,689,921 as of November 12, 2025. Nasdaq closing prices on November 13, 2025 were
Tevogen Bio Holdings Inc. reported Q3 results marked by continued investment and tight liquidity. The company posted a net loss of
Cash was
Management states these resources, together with a remaining